Closed · RFA-CA-13-501 · CFDA 93.395 · Discretionary
Limited Competition: Adult Brain Tumor Consortium (ABTC) (UM1)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $2M
- Award range
- Closed
- Status
- September 16, 2013
- Close date
- 1
- Expected awards
The verdict
Limited Competition: Adult Brain Tumor Consortium (ABTC) (UM1) is a closed discretionary listing from National Institutes of Health that offered Up to $2,000,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $2M
- award range
- Closed
- application status
- 1
- expected award
- 93.395
- CFDA program
Archived opportunity record
Limited Competition: Adult Brain Tumor Consor… is closed (last close September 16, 2013). The parent program page for CFDA 93.395 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed September 16, 2013
Est. Total Funding
$2,000,000
Expected Awards
1
Instrument
Cooperative Agreement
Description
The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue the program of the National Cancer Institute (NCI) for the development of new anticancer therapies for adult patients with brain tumors, especially glioblastoma multiforme (GBM). This limited competition FOA solicits a single application from the current awardee of the Adult Brain Tumor Consortium (ABTC). The ABTC is a NCI-funded clinical trials group that performs clinical research on the treatment of patients with GBM. In this funding period, the ABTC is expected to remain focused on the early stage development of new agents for treatment of GBM. However, in addition to identifying agents with antitumor activity in patients participating in Phase I and II clinical trials, the Consortium will be expected to expand and enrich its translational research. These aspects include increased emphasis on the identification of the effects of anticancer agents on their intended targets and other studies to increase understanding of biological and molecular factors that may improve the response of GBM to new agents. ABTC must be capable of conducting comprehensive pharmacokinetic and pharmacodynamic evaluations, characterization of drug effects on relevant cellular targets (using appropriate biospecimens) and integrating such findings.
Catch-all / unrestricted eligibility mark · RFA-CA-13-501
Grants.gov marks Limited Competition: Adult Brain Tumor Consor… with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 187 other National Institutes of Health listings share this exact eligibility-code string (2% of 12,420).
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Cancer Treatment Research
National Institutes of Health
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Limited Competition: Adult Brain Tumor Consor… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.395 may publish future NOFOs under the same assistance listing. Open program
- Cancer Treatment Research indexes 60 Grants.gov listings in this extract. Program profile
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |